Zulviqar Anwer
Physician & Emergency Care Provider, India
Title: Qualitative efficacy of the herbal medication of Unani (Indo-Greek) origins in treating patient suffering from acute ischemic stroke with complete loss of speech
Biography
Biography: Zulviqar Anwer
Abstract
Severe case of known prognosis of acute ischemic stroke with right hemiplegia and complete loss of speech was successfully treated and significantly recovered. A 75 years old male with known history of hypertension and chronic obstructive pulmonary disease (COPD) was shifted from intensive care unit (ICU) with medical complications involving acute ischemic stroke, right hemiplegia and complete loss of speech. The patient was shifted after three days of admission in the ICU to the Unani Herbal Medicine Unit of the HNA Clinic, Bijnor. The diagnostics including Contrast MRI Stroke Panel of the brain infirmed large acute infarct in left medial fronto-parietal lobe involving corpus callosum. There were multiple sub-acute to chronic lacunar infarcts in bilateral frontal and parietal lobes. Moreover, diffuse cerebral atrophy was noticed. The pathological examinations of the blood revealed leukocytosis. However, the random blood sugar and lipid profiles were found to be within the normal limits as was the Liver function test and Renal function test. On further examination, his temperature was found 102.7°F, blood pressure at 106/64 mm Hg, heart rate 140 beats/minute, and oxygen saturation at 93% on room air as noted on first herbal clinic’s visit. The pre-herbal treatment medicament included Statin, Ecosprin, Pantoprazole, Citicholine, Telmisartan, Amlodipine, Vitamin B12 and Doxofylline and injectable. All the medicines except Ecospirin, Statin, and Vitamin B12 were discontinued immediately. The patient was put on Unani medicine, Khamira Abresham Hakeem Arshad Wala, Arq Gao Zaban, Mau’l Asl, Dawaul Misk, Habb e ayarij in addition to Ecospirin, Statin, and Vitamin B12 in a defined dose regimen for all the medicines including herbals and non-herbals. The therapeutic plan and the dosage regimen continued for 4 weeks and the patient showed satisfactory recovery of speech. He also regained satisfactory movements of his upper and lower limbs in significant strength and quality. A detailed presentation of the case will be undertaken.